Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device captures heart artery clues for tailored therapies

NCT ID NCT06259019

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new device that collects blood samples directly from heart arteries in 300 people with coronary artery disease. Researchers will analyze these samples to find biomarkers that could help develop personalized treatments. The goal is to better understand the disease and improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Stage 1 screening inclusion: 1. ≥18 years of age, have capacity and be willing to provide informed consent to participate 2. Clinical evidence of obstructive coronary artery disease and be scheduled for either: 1. Elective coronary angiography +/- proceed for stable angina OR 2. Elective PCI for stable angina with known bystander disease OR 3. Angiography +/- proceed for Troponin negative unstable angina Stage 2 screening inclusion: Suitable lesion identified meeting angiographic criteria for LBS deployment and Cardiologist comfortable to deploy OCT and LBS on study lesion before carrying out PCI on any lesion Exclusion Criteria: Stage 1 screening exclusion: 1. Myocardial Infarction within 30 days of procedure. 2. Chronic renal failure (eGFR\<30ml/min/1.73m2). 3. Contrast allergy. 4. Hypotension, shock or haemodynamic instability. 5. Ventricular arrhythmia. 6. Chronic Heart Failure (NYHA ≥ 3) or LVEF ≤ 30%. 7. Immunocompromised or receiving immunosuppressant therapy. 8. Any active disease that in the opinion of the investigator makes the subject unsuitable for the research procedure or subject life expectancy less than 1 year. 9. Active infection or sepsis (significant CRP elevation and/or requiring antibiotics). 10. Active systemic inflammatory condition. 11. Inability to receive anticoagulants or antiplatelets or uncorrected bleeding disorder or deranged platelet count. 12. Is pregnant. 13. Deemed high clinical risk or unsuitable for the procedure for any reason by the treating clinician. Stage 2 screening exclusion: 1. Target lesion is in the left main coronary artery. 2. Unsuitable coronary anatomy (vessel tortuosity \[\>45 degree bend\], moderate/ severe calcification angiographically, ostial disease). 3. Presence of thrombus in the target vessel. 4. Prior PCI or stent or graft in vessel identified for LBS sampling. 5. No clinical indication for either a PCI or a pressure wire assessment on any lesion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bristol Heart Institute

    RECRUITING

    Bristol, United Kingdom

  • Norfolk and Norwich Hospital

    RECRUITING

    Norwich, United Kingdom

  • Royal Bournemouth Hospital

    RECRUITING

    Bournemouth, United Kingdom

  • Royal Papworth Hospital

    RECRUITING

    Cambridge, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.